Envafolimumab for advanced cancers after other treatments
Treatments studied
Part of Cancer clinical trials.
This trial tests envafolimumab, an immune therapy given alone, in people with advanced solid tumors that can’t be removed by surgery or have spread. It’s for patients whose cancer has grown despite (or they couldn’t tolerate) standard treatment, and it aims to find whether this drug can shrink tumors or slow growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old and can sign informed consent.
- You have advanced solid tumors that can’t be removed or have metastasized (confirmed by lab tests on tissue or fluid).
- Your cancer has either progressed after standard first-line treatment or you couldn’t tolerate it, with no good other options.
- You have not had any immune checkpoint inhibitor treatment before.
- Your cancer type must be one of the listed eligible cancers, and MSI-H tumor results are not allowed.
- You have a measurable tumor spot on scans and enough body organ function to safely take the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (KGX101 with envafolimab) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if these drugs are safe and could help shrink tumors.
This Phase 2 trial tests whether envafolimab alone or combined with lenvatinib can slow or shrink advanced endometrial (uterine) cancer. It’s for people whose cancer has grown again or spread and who didn’t do well with standard platinum chemotherapy.
This study tests a new immune cell therapy (EVM16) given alone or with another drug (tislelizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests a new immunotherapy (Envafolimab) combined with standard chemotherapy before and after surgery for stage III non-small cell lung cancer that can be removed. The goal is to see if adding Envafolimab helps shrink the tumor and improve outcomes compared to chemotherapy alone.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.